BridgeBio Pharma annual revenue
2019
2020
2021
2022
2023
2024
2025
BridgeBio Pharma Revenue Growth & History (BBIO)
BridgeBio Pharma reported $502.1M in revenue for fiscal 2025, an increase of 126.26% from the previous fiscal year.
View full BridgeBio Pharma company overviewBridgeBio Pharma annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $502.1M | $280.2M | +126.26% |
| 2024 | 2024-12-31 | $221.9M | $212.6M | +2285.27% |
| 2023 | 2023-12-31 | $9.3M | −$68.3M | −88.02% |
| 2022 | 2022-12-31 | $77.6M | $7.9M | +11.38% |
| 2021 | 2021-12-31 | $69.7M | $61.5M | +745.14% |
| 2020 | 2020-12-31 | $8.2M | −$32.3M | −79.66% |
| 2019 | 2019-12-31 | $40.6M | — | — |
BridgeBio Pharma quarterly revenue
Q3.19
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $243.7M | $133.1M | +120.39% |
| Q1 2026 | 2026-03-31 | $194.5M | $77.9M | +66.78% |
| Q4 2025 | 2025-12-31 | $154.2M | $148.3M | +2521.18% |
| Q3 2025 | 2025-09-30 | $120.7M | $118.0M | +4318.01% |
| Q2 2025 | 2025-06-30 | $110.6M | $108.4M | +4999.86% |
| Q1 2025 | 2025-03-31 | $116.6M | −$94.5M | −44.76% |
| Q4 2024 | 2024-12-31 | $5.9M | $4.1M | +237.08% |
| Q3 2024 | 2024-09-30 | $2.7M | −$1.4M | −33.22% |
| Q2 2024 | 2024-06-30 | $2.2M | $527,000 | +32.11% |
| Q1 2024 | 2024-03-31 | $211.1M | $209.3M | +11461.88% |
| Q4 2023 | 2023-12-31 | $1.7M | −$125,000 | −6.68% |
| Q3 2023 | 2023-09-30 | $4.1M | $3.8M | +1110.36% |
| Q2 2023 | 2023-06-30 | $1.6M | −$72.1M | −97.77% |
| Q1 2023 | 2023-03-31 | $1.8M | $132,000 | +7.79% |
| Q4 2022 | 2022-12-31 | $1.9M | −$11.0M | −85.49% |
| Q3 2022 | 2022-09-30 | $338,000 | −$2.0M | −85.58% |
| Q2 2022 | 2022-06-30 | $73.7M | $19.7M | +36.51% |
| Q1 2022 | 2022-03-31 | $1.7M | $1.2M | +266.67% |
| Q4 2021 | 2021-12-31 | $12.9M | — | — |
| Q3 2021 | 2021-09-30 | $2.3M | −$5.8M | −71.16% |
| Q2 2021 | 2021-06-30 | $54.0M | — | — |
| Q1 2021 | 2021-03-31 | $462,000 | — | — |
| Q3 2020 | 2020-09-30 | $8.1M | −$18.6M | −69.61% |
| Q3 2019 | 2019-09-30 | $26.7M | — | — |
BridgeBio Pharma revenue growth trends
Over the last five reported fiscal years, revenue grew from $8.2M to $502.1M, a compound annual growth rate of 127.44%. BridgeBio Pharma's latest reported quarter, Q2 2026, generated $243.7M in revenue, an increase of 120.39% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review BridgeBio Pharma source filings ↗